PCSK9:

Ding-Qiang Chen1,2, Wen-Bin Xu3, Ke-Yi Xiao1,2

  • 1Department of Orthopedics, The First Affiliated Hospital of Xiamen University, Xiamen, China.

PubMed
概括

根据孟德尔的随机化分析,蛋白转化酶子素/素9型 (PCSK9) 抑制剂可能会增加骨质疏松症的风险. 然而,3-基-3-甲基氨酸共因子A减少酶 (HMGCR) 抑制剂与骨密度变化没有关联.